Skip to main content
INCR
NASDAQ Life Sciences

InterCure Regains Nasdaq Compliance, Averting Delisting Threat

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Pharmaceutical Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$5.39
Mkt Cap
$63.848M
52W Low
$3.4
52W High
$8.45
52W Position info
59% above low
Off High info
36% below high
Rel. Volume info
0.3× avg
Market data snapshot near publication time

INCR sits 59% above its 52-week low of $3.4 on light trading volume (0.3× avg).

Summary

InterCure Ltd. announced it has regained compliance with Nasdaq's minimum bid price requirement, successfully resolving the delisting notice received earlier this month.


Key Events · Corporate Governance and Compliance · INCR

  • Regains Nasdaq Compliance

    InterCure received confirmation from Nasdaq that it has regained compliance with the $1.00 minimum bid price requirement.

  • Averts Delisting

    This resolves the delisting notice received on September 1, 2026, which stated the company had not met the compliance deadline.

  • Follows Reverse Stock Split

    Compliance was achieved after the company's ordinary shares traded at or above $1.00 for 10 consecutive business days, following a 1-for-5 reverse stock split executed on August 24, 2026.


Analysis · INCR · Life Sciences

This filing confirms that InterCure has successfully met Nasdaq's minimum bid price requirement, following a 1-for-5 reverse stock split on August 24, 2026. The company had previously received a delisting notice on September 1, 2026, after failing to meet the compliance deadline. Regaining compliance removes a significant overhang and the immediate threat of delisting, which is crucial for maintaining investor confidence and liquidity on a major exchange.

How filings like this one have moved

In the 30 days to Sep 10, 2026, 35.6% of the 1819 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, INCR was trading at $5.39 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $63.8M. The 52-week trading range was $3.40 to $8.45. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

INCR - Latest Insights

INCR
Aug 27, 2026, 11:38 AM EDT
Filing Type: 6-K/A
Importance Score:
7
Price at Filing: $5.74
Real-time Price: $5.25 info
Change: -$0.490 (-9%) info
Market Cap: $62.19M info
INCR
Aug 26, 2026, 4:06 PM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $5.85
Real-time Price: $5.25 info
Change: -$0.600 (-10%) info
Market Cap: $62.19M info
INCR
Aug 24, 2026, 7:05 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $1.15
Real-time Price: $5.25 info
Change: Reverse Stock Split info
Market Cap: $62.19M info
INCR
Aug 24, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $1.15
Real-time Price: $5.25 info
Change: Reverse Stock Split info
Market Cap: $62.19M info
INCR
Jul 22, 2026, 4:06 PM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $0.940
Real-time Price: $5.25 info
Change: Reverse Stock Split info
Market Cap: $62.19M info